Its optimized derivative, BIO203, shows enhanced therapeutic potential via several key improvements: (i) structural modifications enhance ocular bioavailability and pharmacokinetics; (ii) it suppresses A2E-induced inflammatory markers (IL-6, IL-8) and VEGF; and (iii) prolonged oral administration over 6 months maintains retinal structure and electrophysiological function in AMD models (blue light-exposed rats and Abca4−/−Rdh8−/− mice) [70]. This evidence concerns the gene ABCA4 and age-related macular degeneration.